Home
overview

SMi is delighted to announce the 4th annual Peptides conference returning to London in 2017!


In the past few years, new technological advancements in the pharma industry have influenced the growth of the global peptide therapeutics market, which is now estimated to reach US $23.70 billion by 2020, with an increased number of peptides now in the pipeline of many biotech companies.


Peptide manufacturers and suppliers have been developing and implementing new technologies to improve the peptide production, reduce manufacturing costs, and allow for more accurate formulations to enhance overall drug delivery. In addition, as cancer has been the most prominent sector in peptide therapeutics and is further expected to stay at the top, the market has been largely driven by the increased demand for peptides in cancer treatment. The increase in collaborations between biotech companies has also contributed to the market growing at this rate.


SMi’s 4th annual Peptides conference will give you the perfect platform to network, collaborate and learn over 2 days, featuring various key presentations by senior level industry professionals. With topics such as peptide formulation and delivery, as well as new advances in alternative peptide analysis technologies, Cell Penetrating Peptides, enhancements in synthesis mechanisms, analytical monitoring techniques, and many more.


You will have the opportunity to gather valuable new insight on assessing biophysical characterization, extending half-life, new formulations and routes of administration, and other pressing matters in the peptides industry.

 

http://bit.ly/2kG3Ei2

  • Gather more in-depth knowledge about using LC-MS applications for peptide purification from the 4 key sessions in the Liquid Chromatography and Mass Spectrometry Techniques stream
  • Listen to informative presentations on Protein-Protein Interactions, featuring discussion points on antibodies, small molecule drug discovery and peptidomimetic inhibitors
  • Learn more about peptide characterisation from our expert speakers discussing stability, purification, synthesis, and other peptide properties
  • Hear about strategies for peptide half-life extension, the new technologies used in therapeutic peptide development, production and manufacturing, and what the future trends are for peptides in the biopharmaceutical industry

Previous attendees included:

 

Abzena; Albumedix; Almac Group; AmbioPharm; Bachem; Bachem Americas; Bachem Americas, Inc.; Bicycle Therapeutics; Bicycle Therapeutics Limited; BUCHI UK Ltd ; Chemi Spa; Complix NV; Cupid Peptide Company; Cupid Peptides ; Cyclogenix Ltd; DAISO Fine Chem GmbH; Haemostatix Ltd; Ipsen; Ipsen Research Laboratories; IRBM Science Park; Kition Research Limited; Ludwig Institute for Cancer Research; Marble Pharma Consult, sprl; MedImmune; Ministry Of Foreign Affairs; MorphoSys AG; MRC Technology; Pepticom LTD; Protagonist Therapeutics; Proxima Concepts Ltd; Sanofi-Aventis; Sanofi-Aventis Germany GmbH; Swedish Biomimetics 3000® Ltd; UCL School of Pharmacy; UCL/Astrazeneca; University Of Bristol; Zealand Pharma; Zealand Pharma A/S;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

John Reilly

John Reilly, Senior Research Investigator, Novartis Institutes for BioMedical Research
View Bio

9:10 Antibody-enabled small molecule drug discovery

Alastair Lawson

Alastair Lawson, Research Fellow, Vice President Structural Biology, UCB
View Bio

  • Protein-protein interactions
  • Conformational definition of target proteins
  • Allosteric modulation of dynamics
  • Fragment library design and screening
  •  

    9:45 Understanding the Structure Activity Relationship of the Nrf2-KEAP1 protein-protein interaction site using an Nrf2-neh2 peptide library design approach

    Elisabetta Bianchi

    Elisabetta Bianchi, Head of Peptide Chemistry , IRBM Science Park
    View Bio

  • Activation of innate antioxidant responses holds much therapeutic potential in neurodegenerative diseases, such as Huntington’s disease
  • Keap1-Nrf2 pathway plays a central role in cell protection against oxidative and electrophilic stress
  • Structure activity relationship (SAR) studies were performed on Nrf2 to identify peptide inhibitors of the Nrf2/Keap1 protein-protein interaction
  • Inspiring medicinal chemistry efforts towards peptidomimetics and macrocyclic inhibitors development

     

  • 10:20 Morning Coffee

    10:50 Synthesis of novel peptidomimetic inhibitors of Caspase I

    Craig Harris

    Craig Harris, Head of Research Synthesis, Nestlé Skin Health
    View Bio

  • Proteomics and transcriptomic studies have shown a strong induction of IL-1β expression in acne inflammatory skin lesions
  • IL-1β usually exists in its pro-form which is cleaved to its active form by the aspartic cysteine protease Caspase-1 upon inflammatory stimulus
  • Blocking Caspase I, therefore, presents an attractive option for the development of a new generation of anti-acne medicine
  • This presentation will concentrate on the synthesis of novel peptidomimetic inhibitors of Caspase I

     

  • 11:25 Combinatorial Peptide Nanotechnology for Drug Discovery

    Roger New

    Roger New, Co-founder & CSO, Proxima Concepts Ltd
    View Bio

  • Peptide nondomains
  • Receptor agonists
  • A priori drug discovery
  • From test tube to whole organism

     

  • 12:00 Networking Lunch

    13:10 Optimizing Permeability and Bioavailability of Peptide Macrocycles

    David  Price

    David Price, Senior Director, Internal Medicine, Pfizer
    View Bio

  • Prospective design of cell permeable macrocycles
  • Use of biophysical techniques
  • Future directions

  • 13:45 Fusion Strategy for the Recombinant Expression of Therapeutic Peptides in Microbial

    Cecile Brocard

    Cecile Brocard, Director Downstream Development, Boehringer Ingelheim
    View Bio

  • Non-Platform Process
  • Expression in E. coli, Inclusion Bodies and Protein Refolding
  • Protease Fusion Technology
  • Production of Therapeutic Peptides at Industrial Scale

     

  • 14:20 From peptide lead candidate to pharmaceutical drug product

    Vincent Bille

    Vincent Bille, Managing Director, Marble Pharma Consult
    View Bio

  • Process development, scaling-up and validation
  • Characterisation and process validation
  • Specifications and registration
  • Specific challenges associated with contract manufacturing service providers

  • 14:55 Afternoon Tea

    15:25 High Throughput Purification and Characterization of Peptides Using LC/MS/ELSD Techniques

    Bhagyashree Khunte

    Bhagyashree Khunte, Senior Principal Scientist, Pfizer
    View Bio

  • Peptide QC
  • Purity analysis using LC/MS/ELSD techniques
  • Peptide purification
  • High Throughput purification workflow
  • 16:00 LC-MS a key technique to understanding the fate of impurities in Ferring’s synthetic therapeutic peptides

    Jörgen Kjellgren Sjögren

    Jörgen Kjellgren Sjögren, Senior Research Scientist, Ferring Pharmaceuticals A/S
    View Bio

  • LC-MS a great tool to understand fate of impurities
  • Separation is crucial as well as identification of impurities
  • Identification of impurities originating from starting material, synthesis, purification and degradation of peptides
  • Examples from Ferring’s synthetic peptide portfolio

     

  • 16:35 Mass-spectrometry based immunopeptidomics for personalised cancer immunotherapy

    Michal Bassani-Sternberg

    Michal Bassani-Sternberg, Head of Immunopeptidomics Unit, CHUV and The Ludwig Cancer Institute
    View Bio

  • Biochemical extraction of HLA binding peptides form tumour tissues
  • Advanced mass-spectrometry analyses for identification and validation of HLA binding peptides
  • Immunopeptidomics in combination with genomics for identification of clinically relevant neo-antigens 
  • Prioritisation of tumour antigens for vaccination

     

  • 17:10 Chairman’s Closing Remarks and Close of Day One

    John Reilly

    John Reilly, Senior Research Investigator, Novartis Institutes for BioMedical Research
    View Bio

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Lutz Jermutus

    Lutz Jermutus, Senior Director & Product Development Team Leader, MedImmune
    View Bio

    9:10 Recent Progress in the Development of Once-Weekly GLP-1 Receptor Agonists

    Dieter Kadereit

    Dieter Kadereit, Lab Head, Peptides & Insulins, IDD, R&D, Sanofi
    View Bio

  • Strategies for half-life extension
  • Established products in the GLP-1 field
  • Emerging technologies, including own data
  •  

    9:50 Extending Drug Half-Life to Achieve Monthly Dosing? The Potential of Veltis® Engineered Albumins for Optimised Dosing

    Joanna Hay

    Joanna Hay, Science Manager, Albumedix
    View Bio

  • Short circulatory half-life represents a major obstacle for many peptide-based therapeutics
  • This can be significantly improved by conjugation or fusion to albumin, due to increased size and recycling via the neonatal Fc receptor (FcRn)
  • The increased FcRn affinity of the Veltis® engineered albumins translates to more than doubling of the already long half-life of native sequence albumin
  • We will describe rationally engineered albumins and their application to improve delivery of peptides

  • 10:30 Morning Coffee

    11:00 From challenging peptide to drug candidate – the dasiglucagon story

    Marie Skovgaard

    Marie Skovgaard, Director Medicinal Chemistry, Zealand Pharma
    View Bio

  • Learnings from native glucagon
  • Optimisation of soluble and chemically stable glucagon analogs 
  • Clinical summary
  • 11:40 Peptides in the biopharmaceutical industry today and tomorrow

    Frank Thielmann

    Frank Thielmann, PMO & Operational Excellence Lead, Novartis
    View Bio

  • Small versus big molecules – benefits and differences in development & manufacturing of peptides
  • Industrial pipelines and disease areas addressed by biotherapies
  • NBEs versus NCEs
  • Future trends in manufacturing
  •  

    12:20 Networking Lunch

    13:30 Conquering a peptide optimisation challenge using protein engineering techniques and deliberate potency reduction

    Jonathan Davis

    Jonathan Davis, Principal Scientist, Bristol-Myers Squibb
    View Bio

  • Challenge: Optimising gp41-binding peptide to be a component of a tri-functional therapeutic
  • Generated libraries of variant peptides fused to a globular protein, expressed and purified in E. coli
  • Reduced the potency of the parental peptide via truncation, to allow favourable mutations to be recognised
  • Final peptide became part of a tri-specific biologic therapeutic with picomolar potency and broad spectrum against HIV

     

  • 14:10 Optimisation of peptide stability

    Martin Will

    Martin Will, Section Head MedChem, Sanofi
    View Bio

  • Physical and chemical stability
  • Methods for determination of physical and chemical stability
  • Optimisation of peptide stability
  •  

    14:50 ReadyFlow - a first in class coagulant for controlling surgical bleeding

    Renata Zbozien

    Renata Zbozien, Vice President R&D, Haemostatix Ltd
    View Bio

  • Unmet needs in the control of surgical bleeding and key factors to determine success
  • HX-P12 peptide: a first in class peptide coagulant
  • Design of a particulate hydrogel formulation
  • Current ReadyFlow formulation; challenges and progress

  • 15:30 Afternoon Tea

    16:00 The use of high resolution mass spectrometry applications for both development and commercial peptides

    Marion King

    Marion King, Analytical Development Manager, Ipsen
    View Bio

  • Mass Spectrometry of peptides that involve ligation technologies
  • Mass Spectrometry for confirming the removal of solid phase coupling reagents
  • Mass Spectrometry for impurity identification in life cycle management activities

     

  • 16:40 Purification, Characterization and Physicochemical Properties of Peptides within Discovery Chemistry

    John Reilly

    John Reilly, Senior Research Investigator, Novartis Institutes for BioMedical Research
    View Bio

  • Chromatographic purification strategies for cyclic and linear peptides including SFC, LC and Flash methodologies
  • Stoichiometry of final salt forms using Ion Chromatography
  • Extraction strategy to remove TFA from final products
  • Physicochemical Trend Analysis on final products

     

  • 17:20 Chairman’s Closing Remarks and Close of Day Two

    Lutz Jermutus

    Lutz Jermutus, Senior Director & Product Development Team Leader, MedImmune
    View Bio

    +

    FEATURED SPEAKERS

    Alastair Lawson

    Alastair Lawson

    Research Fellow, Vice President Structural Biology, UCB
    Cecile Brocard

    Cecile Brocard

    Director Downstream Development, Boehringer Ingelheim
    Craig Harris

    Craig Harris

    Head of Research Synthesis, Nestlé Skin Health
    Elisabetta Bianchi

    Elisabetta Bianchi

    Head of Peptide Chemistry , IRBM Science Park

    Alastair Lawson

    Research Fellow, Vice President Structural Biology, UCB
    Alastair Lawson

    Alastair has been closely involved with the discovery of UCB/Celltech’s therapeutic antibodies, including Mylotarg, Cimzia, romosozumab, inotuzumab ozogamicin, dapirolizumab pegol, olokizumab, bimekizumab and UCB7665. Alastair led the development of UCB’s proprietary antibody variable region discovery platform, and is now applying structure-based, rational design to antibody discovery. He pioneered UCB’s small molecule protein/protein interaction initiative, in which information derived from antibodies is applied to the discovery and design of new chemical entities. Current research interests include the use of function-modifying antibody fragments to define specific conformations of target proteins, linking X-ray crystallography, molecular dynamics simulations and antibody technology to small molecule fragment screening.

    Alessandro Butté

    Lecturer, ETH Zürich
    Alessandro Butté

    Workshop Leader B

    Alessandro Butté received his Ph.D. in Chemical Engineering in 2000 from ETH Zurich. After a two-year post-doc at the Georgia Institute of Technology, he join the group of Prof. Morbidelli at ETH Zurich and completed his habilitation in 2008. During this period, his research activities focused on polymer engineering, production of nano-materials for protein purification (monoliths by reactive-gelation) and chromatography purifications of peptides, proteins and Mabs. In 2008, he joined Lonza as leader for downstream activities in the sectors small molecules and peptides and as project manager. He was also involved in the pilot program to introduce Quality by Design into R&D. In 2013, he joined back ETH as senior researcher. His current main research area is focused on the use of big data, advanced statistics and machine learning in combination with classical mechanistic models for risk management in R&D and manufacturing of biomolecules. He is author of more than 60 papers on international peer reviewed journals and several book chapters.

    Bhagyashree Khunte

    Senior Principal Scientist, Pfizer
    Bhagyashree Khunte

    Bhagyashree Khunte is a Senior Principal Scientist in the R&D division at Pfizer Inc. with over 15 years of experience in separation sciences. She leads the high throughput singleton and library purification group that provides purification support to Medicinal Chemistry lines. Her work has included enhancing purification technologies to enable purification of beyond rule of five molecules including chemical probes, peptides, oligonucleotides, and protein and antibody drug conjugates.

    Cecile Brocard

    Director Downstream Development, Boehringer Ingelheim
    Cecile Brocard

    Cécile Brocard studied Biochemistry and Molecular Cell Biology in France, holds a PhD in Biochemistry from the University of Vienna (Austria) and has over 20-year experience in protein biochemistry.

    Currently she is leading Downstream Development in Process Science at Boehringer Ingelheim Regional Center Vienna. As Head of Downstream Development she is responsible for DSP processes development for non-platform recombinant proteins expressed in microbial including, clinical supplies phase I/II/III and tech transfer to production. She heads a group composed of two downstream development units and a non-GMP pilot plant. Besides, she is critically involved in driving technology programs and strategic initiatives to develop innovation and improve process flows.

    Craig Harris

    Head of Research Synthesis, Nestlé Skin Health
    Craig Harris

    Dr. Craig Harris obtained his B.Sc. and Ph.D. at the University of Manchester (UMIST) in 1997. After a brief stay in PR&D at AZ, from 1999 he moved to Discovery Research working in the Oncology iMed for AZ working principally on kinase inhibition initially at the Alderley Park site then at the Reims site, France. After the closure of the Reims site in 2012, he was taken on as Head of Research Synthesis at for then Galderma (now, Nestlé Skin Health) Research Chemistry. In 2014, he was nominated as Senior Expert Scientist for Chemical Sciences.
    During his career, he has won several prizes for publications and innovation in synthesis. Craig’s main interests lie in the word ‘Lean’ applied to chemical research: Rapid & selective synthesis of novel molecules for pharmacological targets. In addition to his background in the synthesis of novel kinase inhibitors as anti-cancer agents, Craig has developed a particular experience in the synthesis of peptidomimetics for targets in drug discovery.

    David Price

    Senior Director, Internal Medicine, Pfizer
    David  Price

    David A. Price currently holds the position of Senior Director in the Cardiovascular and Metabolic Diseases department within Pfizer. David obtained a B.Sc. (First Class Hons.) and Ph.D. from the University of Nottingham, UK, after which he carried out postdoctoral research at Colorado State University with Prof. Meyers. This work was directed towards the asymmetric synthesis of azasugars for the potential treatment of HIV. In 1998, David returned to the UK to take up a position as a Team Leader in Discovery Chemistry with Pfizer. In 2007, David transferred to Pfizer’s research headquarters in Groton, CT to assume a leadership role within the bone research group and then relocated to Cambridge MA to help lead the diabetes/obesity medicinal chemistry group. During his tenure with Pfizer, David has worked on projects to develop drugs for a wide variety of diseases including HIV/AIDS, respiratory diseases and, most recently, type II diabetes contributing to many clinical candidates that progressed to man. His most significant achievement has been the discovery of the marketed drug Maraviroc (Selzentry®), which received FDA approval in 2007 for the treatment of HIV infection.

    Dieter Kadereit

    Lab Head, Peptides & Insulins, IDD, R&D, Sanofi
    Dieter Kadereit

    Dieter Kadereit studied chemistry at the University of Hannover in Germany. After spending a year in Stanford, California with Prof. Wender he moved to the RWTH Aachen for his diploma research with Prof. Bolm and finally to the University of Karlsruhe for his PhD with Prof. Waldmann.
    In the year 2000 Dieter joined Aventis as a laboratory head in chemistry. Soon he also became project team leader for his project and remained in that double role through several reorganizations and in different departments. Today he is working as laboratory head and project team leader in the Peptides & Insulins group in Sanofi’s Integrated Drug Discovery Research Platform.

    Elisabetta Bianchi

    Head of Peptide Chemistry , IRBM Science Park
    Elisabetta Bianchi

    Elisabetta Bianchi has been the Head of Peptide Chemistry at IRBM Science Park Pomezia (Italy) since 2010. In 2014 she obtained the Italian National Academic Qualifications as associate professor in Organic Chemistry and Molecular Biology. She started her career in the pharmaceutical industry in the Peptide Chemistry Group at Eniricerche followed by positions in Sclavo and Menarini Ricerche before joining IRBM in 1991. After full IRBM acquisition by Merck Research Laboratories in 2007 she was appointed Senior Investigator in the Peptide Center of Excellence at Merck. As project leader and member of Merck Early Development Teams she contributed to the preclinical and clinical development of peptide vaccines and peptide therapeutics. She is the author of 67 scientific publications in peer-reviewed journals and inventor in more than 30 patent applications.

    Frank Thielmann

    PMO & Operational Excellence Lead, Novartis
    Frank Thielmann

    Dr Thielmann graduated from University of Duesseldorf, Germany in 1996 with a diploma in Chemistry. This was followed by a PhD in Physical Chemistry in 1998 in the area of materials characterisation. Frank then worked for a private materials testing institute in Hannover, Germany before joining Surface Measurement Systems UK (SMS) in 2000. He stayed with SMS for eight years in different roles including global Head of Application Science. In this role, he was heavily involved in the development of novel characterisation methods for the challenges in the modern (bio)pharmaceutical industry with focus on solid dosage forms. Frank joined Novartis Pharma (Basel, Switzerland) in July 2007 as Formulation Lab Head. From August 2009 until February 2011 he managed the inhalation & device development group at the Horsham site, UK. Upon his return to Basel he took on the responsibility for the local inhalation technology platform until February 2012. Subsequently he joined Novartis Technical Operations where he was leading the setup of a new inhalation manufacturing facility and the transfer of the corresponding portfolio.
    In December 2016 Frank joint the Biologics Technical Development & Manufacturing department as the Lead for PMO & Operational Excellence.
    Dr Thielmann is member of the Steering Committee of the Material Science Focus Group in the British Academy of Pharmaceutical Sciences. He is an author and co-author of more than 25 articles in peer reviewed journals as well as author and co-author of more than 50 oral presentations at international conferences and seminars and over 100 scientific posters.

    Joanna Hay

    Science Manager, Albumedix
    Joanna Hay

    Joanna Hay obtained a B.Sc. in Biochemistry from the University of Birmingham (UK) and a Ph.D. in Biochemistry from University of Leicester. Joanna joined Albumedix in 2006 as a Scientist working with the R&D team on the development and optimization of engineered albumins for half-life extension technology, Veltis®. Currently Joanna is working as a Science Manager in Albumedix, working with drug developers wanting to evaluate the potential of the Veltis in their drug development programs.

    John Reilly

    Senior Research Investigator, Novartis Institutes for BioMedical Research
    John Reilly

    Chair for Day 1

    Dr. Reilly is a Senior Research Investigator in the Department of Global Discovery Chemistry at Novartis Institute of Biomedical Sciences in Cambridge MA, USA. He currently leads the Chemistry Separations support team where there is a focus on providing purification and analytical characterization methodologies to support an expanding Chemistry unit. He completed both MSc. Birkbeck College in 1992 and Ph.D within Analytical Science Imperial College in 2002 after his initial BSc in Chemistry at Reading University in 1989. His research goals include the promotion of chromatographic characterization and purification methods and physicochemical affinity screens to investigate drug-like properties of molecules. Dr. Reilly has published >30 articles in many analytical journals such as J. Chromatography A, J. Med. Chem, J. Pharm. Biomed. Analysis, Chirality and Molecular Pharmacology. Dr. Reilly has been board member of the Chromatography Society in the UK and ChromSoc conference organiser and on the editorial board of “Chromatography Today” and “American Journal of Modern Chromatography.”

    Jonathan Davis

    Principal Scientist, Bristol-Myers Squibb
    Jonathan Davis

    Jonathan Davis received his Ph.D. from UC San Francisco, followed by a post-doc at Harvard Medical School in the labs of Jack Szostak and Gerhard Wagner. He then joined EMD Serono in Billerica, MA, where he invented a platform technology for generating heterodimeric Fcs and developed a novel scaffold based on an artificially-designed protein. He has extensive experience in selection technologies, library design, in silico modeling, and therapeutic discovery. In 2008 he moved to Bristol-Myers Squibb, where he is a Principal Scientists in Molecular Structure and Design, applying his skills to a wide range of challenges in protein and peptide engineering.

    Jörgen Kjellgren Sjögren

    Senior Research Scientist, Ferring Pharmaceuticals A/S
    Jörgen Kjellgren Sjögren

    Masters degree in Analytical Chemistry from Lund University, Sweden, in 1997 and PhD in Organic Chemistry from the Swedish University of Agricultural Sciences in Uppsala 2005. Worked with structure elucidation of peptides for >15 years utilising HPLC/UHPLC, MS and NMR and have >10 years experience of the pharmaceutical industry, 2½ years at Astra Zeneca, Lund, Sweden, and >11 years at Ferring Pharmaceuticals in Copenhagen, Denmark.

    Lutz Jermutus

    Senior Director & Product Development Team Leader, MedImmune
    Lutz Jermutus

    Chair for Day 2

    .

    Marie Skovgaard

    Director Medicinal Chemistry, Zealand Pharma
    Marie Skovgaard

    Marie Skovgaard has an MSc in Biochemistry from University of Copenhagen, Denmark, and a PhD in Bioinformatics from the Danish Technical University. Marie started working with peptides during a PostDoc at Novo Nordisk before joining Zealand Pharma where she has been working with peptide drug development the past 10 years. Marie is currently heading up the Chemistry Department at Zealand Pharma. As Director of Chemistry she is responsible for overseeing peptide design and synthesis for the research pipeline.

    Marion King

    Analytical Development Manager, Ipsen
    Marion King

    Dr. Marion King is the Analytical Development Manager with Ipsen Manufacturing Ireland Ltd. She has over 13 years’ experience in the Pharmaceutical industry with 11 years working in the area of Analytical Development of peptides at Ipsen. Marion has a BSc in Analytical Chemistry from Cork Institute of Technology and a PhD from Dublin City University. Marion recently completed an MSc in Management and also leads a companywide Analytical Centre of Excellence (ACE) team. Marion is a member of the USP Biologics 1 – Peptides and Insulins Expert Committee and the JS3 Joint Subcommittee on biological reference standards.

    Martin Will

    Section Head MedChem, Sanofi
    Martin Will

    Martin Will received his MSc and PhD in Chemistry (1989) from Johann Wolfgang Goethe University in Frankfurt in Group of Horst Kessler working on conformational analysis of cyclic peptides using NMR and molecular dynamics. He started his industrial career 1989 at BASF where he held various positions in chemo-informatics and analytical chemistry. In 2001 he moved to Aventis (now Sanofi) taking over a position as section head analytical chemistry. His research was focused on new methods for automated structure validation and optimization of drug like properties. Currently, his group has a strong focus on peptide analytics and physico-chemistry.

    Michal Bassani-Sternberg

    Head of Immunopeptidomics Unit, CHUV and The Ludwig Cancer Institute
    Michal Bassani-Sternberg

    Michal Bassani-Sternberg received her PhD degree in Biology (2010) from the Technion - Israel Institute of Technology. From 2011 to 2015 she was a post-doctoral researcher at the Proteomics and Signal Transduction Department, headed by Prof. Matthias Mann at the Max Planck Institute of Biochemistry. She was awarded the Minerva and the Alexander von Humboldt fellowships. She developed mass spectrometry-based workflows for direct identification of HLA binding peptides eluted form tumor specimens and uncovered dozens of new cancer specific antigens including patient’s specific neo-antigens. Currently she is heading the Immunopeptidomics Unit and implements this technology in the Center of Experimental Therapeutics at the CHUV.

    Renata Zbozien

    Vice President R&D, Haemostatix Ltd
    Renata Zbozien

    Renata has experience in drug discovery; the design and synthesis of peptides, and conjugation methods. She is the inventor of the first in class peptide coagulant HX-P12, for treating bleeding during surgery and trauma. HX-P12 formulated as a ReadyFlow formulation won first prize in the Royal Society of Chemistry Emerging Technologies Competition 2015.
    Renata also worked as a research scientist at Amylin Pharmaceuticals in their San Diego research group with a focus on discovery, synthesis and development of novel peptide hormones.
    She carried out post-doctoral research in the USA at Stanford University developing a new type of peptide-based antibiotic.

    Roger New

    Co-founder & CSO, Proxima Concepts Ltd
    Roger New

    Workshop Leader A

    Roger New studied chemistry at Oxford and obtained a PhD in immunology at St Mary’s Hospital, London, before going to work in Liverpool for 14 years, first at the Department of Biochemistry, then at the School of Tropical Medicine and Hygiene. His research activities have centred on the creation of new technologies to improve the therapy of disease, during which time he has devised patented approaches to oral peptide delivery, vaccine carrier systems, and a technology for discovery of new therapeutics. He has acted as expert advisor in numerous institutions at home and overseas, has written a textbook on liposomes, and is honorary lecturer in Pharmaceutics at Kings College London. Dr New’s laboratory was the first to demonstrate the in vivo efficacy of liposomal amphotericin in leishmaniasis, a product which has now been commercialised for over ten years. He went into industry twenty years ago, first in Biocompatibles Ltd, then Cortecs, and is currently Co-founder and Executive Director of the biotech R&D company Proxima Concepts Ltd, with laboratories based in London. Development of the peptide delivery technology invented by Dr New has resulted in a product for oral administration of insulin, now in Phase II clinical trials, and licensed to large pharma in an emerging market. The discovery technology has yielded structures which can act as targeting agents, inhibit enzyme activity or change the behaviour of cells, and one peptide has been developed which is currently undergoing preclinical studies as a treatment for rheumatoid arthritis.

    Vincent Bille

    Managing Director, Marble Pharma Consult
    Vincent Bille

    Dr Vincent R. Bille is the founder and Managing Director of Marble Pharma Consult sprl, an independent firm offering consultancy services to pharmaceutical and biopharmaceutical companies that address all aspects of externalized process and analytical development as well as commercial manufacturing and testing activities.

    Marble Pharma Consult has established a strong track record in international, cross-cultural project and relationship management and provides specific expertise in the areas of GMP-regulated primary and secondary pharmaceutical operations as well as regulatory-enabling activities including quality systems implementation, qualification and validation programs design and execution as well as the related technology transfers.

    Prior to founding Marble Pharma Consult in 2007, Vincent served as Director Sales and Business Development for Lonza (Basel Switzerland), a global contract manufacturing organization. Before joining Lonza, Vincent held various operational and senior management positions with UCB-Bioproducts, a peptide CDMO subsidiary of the biopharmaceutical company UCB (Brussels, Belgium) including the positions of General Manager of the US subsidiary, Director Global Commercial Operations, Peptides and Formulation BU Manager and Operations and Development Manager.

    Vincent Bille holds a Doctorate in Biochemistry (1987) and a Master’s Degree in Administration and Management (1994).

    Sponsors and Exhibitors

    Official Media Partner

    Supporters

    Workshops

    Oral Delivery of Peptides and Proteins
    Workshop

    Oral Delivery of Peptides and Proteins

    Holiday Inn Kensington Forum
    5th July 2017
    London, United Kingdom

    QbD in Process Development and Manufacturing
    Workshop

    QbD in Process Development and Manufacturing

    Holiday Inn Kensington Forum
    5th July 2017
    London, United Kingdom

    VENUE

    Holiday Inn Kensington Forum

    97 Cromwell Road , London, United Kingdom

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Sponsors and Exhibitors


    Bachem

    Sponsors and Exhibitors
    http://www.bachem.com/

    Bachem provides comprehensive services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based APIs. The group has a global reach with more experience and know-how than any other company in the industry. Bachem. Pioneering Partner for Peptides


    Tepnel Pharma Services

    Sponsors and Exhibitors
    http://www.tepnelpharmaservices.com

    Tepnel Pharma Services is an independent Contract Research Organisation which supports the drug development pipeline at the Rx/Dx interface. With over 30 years of experience in supporting pharmaceutical, biopharmaceutical and biotechnology companies through the provision of outsourced cGMP compliant Chemistry, Manufacturing and Control (CMC) and human genetics testing, Tepnel Pharma Services is positioned to provide CMC support for drug development, whilst also providing a companion diagnostic solution which addresses the requirements of personalised and stratified medicines.

    Media Partners


    SciDoc Publishers

    Official Media Partner
    http://www.scidoc.org

    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.

    Media Partners


    Pharmaceutical-Review

    Supporters
    http://www.pharmaceutical-review.com

    Pharmaceutical-review.com is part of Integrated IQ technologies Private Limited(IIQ). A Leading platform for all the Pharma manufacturing companies and buyers across the world.Having a subscriber database of more than 120,000 globally helping the clients to reach their target buyers through our exclusive listing, branding(banner advertisement), e-news letters, e-mail marketing, product reviews, product launch promotions, event marketing, search engine marketing and social media marketing services.


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 116 titles and 200 plus open access journals and print/online book series (Bentham eBooks). Bentham Science answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Drug Metabolism (Impact Factor 5.113) and Current Medicinal Chemistry (Impact Factor 4.859): FREE online journals and information: www.benthamscience.com


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    BioChem Adda

    Supporters
    https://www.biochemadda.com/

    BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!


    International Journal of Biomedical Engineering and Technology

    Supporters
    http://www.inderscience.com/ijbet

    IJBET addresses cutting-edge research in the multi-disciplinary area of biomedical engineering and technology. Medical science incorporates scientific/technological advances combining to produce more accurate diagnoses, effective treatments with fewer side effects, and improved ability to prevent disease and provide superior-quality healthcare. A key field here is biomedical engineering/technology, offering a synthesis of physical, chemical, mathematical and computational sciences combined with engineering principles to enhance R&D in biology, medicine, behaviour, and health. IJBET includes the Asia-Pacific Chapter in Biomedical Wireless Technology (APC-BWT).


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    International Journal of Computational Biology and Drug Design

    Supporters
    http://www.inderscience.com/ijcbdd

    IJCBDD, an International Society of Intelligent Biological Medicine official journal, bridges the gap between two very important, complementary disciplines, computational biology and drug design. Through advances in high-throughput genome sequencing and digital imaging technologies, biocomputing, drug design and medical research have unfolded new, predictive sciences such as genomics, proteomics, lipidomics, metabolomics, cytomics and pharmaconomics. These promote new computational, statistical and biomedical approaches to drug design/development, besides unleashing the potential of significantly more accurate, effective personalised diagnosis, therapeutics and patient care.


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


    Int. J. of Immunological Studies

    Supporters
    http://www.inderscience.com/ijis

    IJIS publishes a broad range of papers on all aspects of immunology from scientists in academic and non-academic organisations as well as business and government worldwide. IJIS is the flagship journal of the Frontiers in Immunology Research Network.


    Labiotech.eu

    Supporters
    http://labiotech.eu

    Labiotech.eu is the leading digital media covering the European Biotech industry. It is used by over 55000 people monthly to keep a watch on the business and innovations of biotechnologies.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    International Journal of Healthcare Technology and Management

    Supporters
    http://www.inderscience.com/ijhtm

    IJHTM is a series emerging from the International Journal of Technology Management. It provides an international forum and refereed authoritative sources of information in the fields of the economics and management of technology in healthcare.


    Medical News Today

    Supporters
    http://www.medicalnewstoday.com

    Medical News Today is the largest independent medical and health news site on the web - with over 10,000,000 monthly unique users it is ranked number one for medical news on all major search engines. Medical News Today is used by pharmaceutical, biotech and health organizations, advertising agencies, PR companies and vertical ad networks to deliver targeted campaigns to HCPs, patients and caregivers. To find out how Medical News Today can help you to reach the right audience contact peter@medicalnewstoday.com or visit www.medicalnewstoday.com.


    Technology Networks

    Supporters
    http://www.technologynetworks.com

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    Farmavita

    Supporters
    http://www.farmavita.net/

    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    International Journal of Biotechnology

    Supporters
    http://www.inderscience.com/ijbt

    IJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. We are an online R&D matching tool that connects Scientifics and organizations involved in discovery, development and delivery of new healthcare products with service and products providers worldwide. Life science information technology is undergoing a revolution. Part of that revolution involves new, unexplored business models, open innovation, open data and collaboration. If you have a project or idea that you would like to propose, develop or run, we can help. A New Collaboration Network Model for Discovery Research and Development • Effective Platform: the 95% • 5.000 registered users // > 15.000 Newsletter subscribers • Geographical background: 45,5% Europe / 37,5% North America / 16,5% Asia / 0,5% ROW • Professional background: Outsourcing Manager, Project Manager, CEO, Business Developer, CSO, Account Manager, Sales & Marketing People, Scientists, R&D. For further information, please visit our website www.contract-biotechnology.com

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.